» Articles » PMID: 35086548

Reactive Oxygen Species Reprogram Macrophages to Suppress Antitumor Immune Response Through the Exosomal MiR-155-5p/PD-L1 Pathway

Overview
Publisher Biomed Central
Specialty Oncology
Date 2022 Jan 28
PMID 35086548
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer cells have an imbalance in oxidation-reduction (redox) homeostasis. Understanding the precise mechanisms and the impact of the altered redox microenvironment on the immunologic reaction to tumors is limited.

Methods: We isolated exosomes from ovarian cancer cells through ultracentrifuge and characterized by Western-blots and Nanoparticle Tracking Analysis. 2D, 3D-coculture tumor model, and 3D live cell imaging were used to study the interactions between tumor cells, macrophages and CD3 T cells in vitro. The role of exosomal miR-155-5p in tumor growth was evaluated in xenograft nude mice models and immune-competent mice models. Flow cytometry and flow sorting were used to determine the expression levels of miR-155-5p and PD-L1 in ascites and splenic macrophages, and the percentages of CD3 T cells subpopulations.

Results: The elevation of reactive oxygen species (ROS) greatly downregulated exosomal miR-155-5p expression in tumor cells. Neutralization of ROS with N-acetyl-L-cysteine (NAC) increased the levels of miR-155-5p in tumor exosomes that were taken up by macrophages, leading to reduction of macrophage migration and tumor spheroid infiltration. We further found that programmed death ligand 1 (PD-L1) is a functional target of miR-155-5p. Co-culture of macrophages pre-treated with NAC-derived tumor exosomes or exosomal miR-155-5p with T-lymphocytes leading to an increased percentage of CD8 T-lymphocyte and a decreased CD3 T cell apoptosis through PD-L1 downregulation. Tumor growth in nude mice was delayed by treatment with NAC-derived tumor exosomes. Delivery of tumor exo-miR-155-5p in immune-intact mice suppressed ovarian cancer progression and macrophage infiltration, and activated CD8 T cell function. It is of note that exo-miR-155-5p inhibited tumor growth more potently than the PD-L1 antibody, suggesting that in addition to PD-L1, other pathways may also be targeted by this approach.

Conclusions: Our findings demonstrate a novel mechanism, ROS-induced down-regulation of miR-155-5p, by which tumors modulate the microenvironment that favors tumor growth. Understanding of the negative impact of ROS on the tumor immune response will improve current therapeutic strategies. Targeting miR-155-5p can be an alternative approach to prevent formation of an immunosuppressive TME through downregulation of PD-L1 and other immunosuppressive factors.

Citing Articles

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.


A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment.

Xiong Z, Huang Y, Cao S, Huang X, Zhang H Front Immunol. 2025; 16:1542326.

PMID: 40013141 PMC: 11860879. DOI: 10.3389/fimmu.2025.1542326.


Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities.

Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B J Inflamm Res. 2025; 18:895-909.

PMID: 39867950 PMC: 11762012. DOI: 10.2147/JIR.S503479.


Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.

Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S J Inflamm Res. 2025; 18:883-894.

PMID: 39867947 PMC: 11760270. DOI: 10.2147/JIR.S498340.


Exosomes: Key Messengers Mediating the Interaction Between Tumor Cells and CD8 T Cells in the Tumor Microenvironment.

Li Y, Yang Q, Li D, Li W, Men W Int J Nanomedicine. 2025; 20():653-667.

PMID: 39835179 PMC: 11745065. DOI: 10.2147/IJN.S502363.


References
1.
Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W . Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017; 147(1):181-187. DOI: 10.1016/j.ygyno.2017.07.007. View

2.
Zhu X, Lang J . The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review. Gynecol Oncol. 2016; 142(1):184-189. DOI: 10.1016/j.ygyno.2016.04.002. View

3.
Morgan M, Liu Z . Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2010; 21(1):103-15. PMC: 3193400. DOI: 10.1038/cr.2010.178. View

4.
Liu J, Fan L, Yu H, Zhang J, He Y, Feng D . Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages. Hepatology. 2019; 70(1):241-258. PMC: 6597282. DOI: 10.1002/hep.30607. View

5.
. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002; 360(9332):505-15. DOI: 10.1016/S0140-6736(02)09738-6. View